AI assistant
INVION LIMITED — Share Issue/Capital Change 2020
Aug 31, 2020
65148_rns_2020-08-31_45858612-2b5a-4521-86e8-5b3f70571582.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [146 x 53] intentionally omitted <==
ASX Announcement
1 September 2020
Lapse of Unlisted Share Options
Invion Limited (ASX.IVX) wishes to advise that on 31 August 2020 18,171,743 unlisted share options with an exercise price of $0.03 per option and an expiry date of 12 February 2023 lapsed, unexercised, following the retirement of Melanie Farris as director.
Investor enquiries
Managing Director & CEO, Craig Newton T: +61 3 9081 6005 E: [email protected]
Media enquires Brendon Lau T: 0409 341 613 E: [email protected]
About Invion
Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by a Sub-Committee of the Board of Invion Limited. For further information please contact [email protected].
About Photodynamic Therapy (PDT)
Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.
Invion Limited ABN 76 094 730 417
Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 9692 7222 W: www.inviongroup.com